Business
Clearmind Medicine CEO Dr. Adi Zuloff-Shani named Delegate to Federal Policy Summit on Psychedelic Medicine in Washington, D.C.
Federal Officials, Researchers, Clinicians and Biopharma Leadership Convened by Psychedelic Medicine Coalition at the National Press Club Vancouver, Canada, May 15, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second-generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that Clearmind Med
About this update from Clearmind Medicine Inc.
[{"type":"image","alt":"Clearmind Medicine Inc.","displaySize":"","headline":null,"caption":"Clearmind Medicine Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":46,"url":"https://media.zenfs.com/en/globenewswire.com/e18eb6f6a6c8d81f644b0fcdb3ee6405"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/o_LPn1dYo7pUzNzxgMYnmw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTY0/https://media.zenfs.com/en/globenewswire.com/e18eb6f6a6c8d81f644b0fcdb3ee6405","width":300,"height":46},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/o_LPn1dYo7pUzNzxgMYnmw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTY0/https://media.zenfs.com/en/globenewswire.com/e18eb6f6a6c8d81f644b0fcdb3ee6405","width":300,"height":46}},"lazy":false},{"type":"text","content":"Federal Officials, Researchers, Clinicians and Biopharma Leadership Convened by Psychedelic Medicine Coalition at the National Press Club","length":137,"tagName":"p"},{"type":"text","content":"Vancouver, Canada, May 15, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second-generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that Clearmind Medicine’s CEO, Dr. Adi Zuloff-Shani, was named a delegate to this year’s annual invite-only federal policy summit that convened on May 14 at the National Press Club in Washington, D.C.","length":554,"tagName":"p"},{"type":"text","content":"The Psychedelic Medicine Coalition’s Federal Policy Summit brought together members of the U.S. Senate and House and key Federal figures to build consensus with global psychedelic biopharma CEOs, noted researchers, eminent clinicians, and professors from some of America’s distinguished academic institutions, including Johns Hopkins, Harvard and Yale Universities.","length":365,"tagName":"p"},{"type":"text","content":"“It was an honor to participate in this important policy summit convening alongside leading researchers, clinicians and policymakers,” said Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine. “We look forward to contributing to constructive dialogue that advances responsible development of psychedelic-derived therapies for patients in need.”","length":340,"tagName":"p"},{"type":"text","content":"Known ...